Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study
Year: 2026
Type: article
Abstract: Autologous stem cell transplantation (ASCT) is an established treatment approach for patients with multiple myeloma (MM) and lymphoma. This prospective pilot study aimed to evaluate the feasibility, efficacy, and safety of a reduced-dose cyclophosphamide plus etoposide (CE) regimen for peripheral blood stem cell (PBSC) mobilization. Fifteen patients (11 with MM and 4 with lymphoma) were enrolled in this single-center prospective study. The mobilization regimen consisted of etoposide (100 mg/m 2 on days 1–2) and cyclophosphamide (1000 mg/m 2 on day 1), followed by granulocyte colony-stimulating factor (G-CSF; 5–10 μg/kg/day) starting on day 7 until completion of collection. The mean total CD34 + cell yield was 7.53 × 10 6 /kg (range, 3.61–15.90). All patients achieved the minimum collection target of ≥ 2.0 × 10 6 CD34 + cells/kg, and 86.7% (13/15) achieved the optimal collection target of ≥ 5.0 × 10 6 CD34 + cells/kg. An optimal collection target was achieved after a single apheresis session in 73.3% (11/15) of patients. Grade 4 neutropenia occurred in one patient (6.7%), and no grade 3–4 thrombocytopenia was observed. In this pilot cohort, a reduced-dose CE regimen combined with G-CSF achieved adequate PBSC collection in all 15 patients without the use of plerixafor. These preliminary findings support the feasibility of this approach in selected patients and warrant further evaluation of its efficacy and safety in larger comparative studies.
Source: Annals of Hematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,590
OpenAlex ID: W7237364340
FWCI:
Cites:
Cited by:
Related to:
